menu
    • menu
    [{"orgOrder":0,"company":"Prothena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Birtamimab","moa":"||Light chain aggregates","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prothena \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Prothena \/ Undisclosed"},{"orgOrder":0,"company":"Prothena","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"Birtamimab","moa":"||Light chain aggregates","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prothena \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Prothena \/ Jefferies"},{"orgOrder":0,"company":"Prothena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Birtamimab","moa":"Light chain aggregates","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prothena \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Prothena \/ Undisclosed"},{"orgOrder":0,"company":"Prothena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"NEOD001","moa":"Light chain aggregates","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prothena \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Prothena \/ Undisclosed"},{"orgOrder":0,"company":"Prothena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"NEOD001","moa":"Light chain aggregates","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prothena \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Prothena \/ Undisclosed"},{"orgOrder":0,"company":"Prothena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"NEOD001","moa":"Light chain aggregates","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prothena \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Prothena \/ Undisclosed"},{"orgOrder":0,"company":"Prothena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"NEOD001","moa":"Light chain aggregates","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prothena \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Prothena \/ Undisclosed"},{"orgOrder":0,"company":"Prothena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"NEOD001","moa":"Light chain aggregates","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prothena \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Prothena \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Amryt Pharma

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Amryt Pharma

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metreleptin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy

                            Details : Metreleptin is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lipodystrophy, Congenital Generalized.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            July 16, 2024

                            Lead Product(s) : Metreleptin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Prothena

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Prothena

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Birtamimab,Bortezomib,Cyclophosphamide

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Jefferies

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Prothena Announces Proposed Public Offering of Ordinary Shares

                            Details : Birtamimab, formerly known as NEOD001, is an investigational monoclonal antibody designed to specifically and selectively target and clear the amyloid that accumulates and causes organ dysfunction and failure in patients with AL amyloidosis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            December 13, 2022

                            Lead Product(s) : Birtamimab,Bortezomib,Cyclophosphamide

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Jefferies

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Prothena

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Prothena

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Birtamimab,Bortezomib,Cyclophosphamide

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Prothena to Present Data on Survival Benefit Observed in Completed Phase 3 Study of Drug Candidate Birtamimab ...

                            Details : Birtamimab is an investigational monoclonal antibody designed to specifically and selectively target and clear the amyloid that accumulates and causes organ dysfunction and failure in patients with AL amyloidosis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 03, 2022

                            Lead Product(s) : Birtamimab,Bortezomib,Cyclophosphamide

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Prothena

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Prothena

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Birtamimab

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis

                            Details : Birtamimab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Immunoglobulin Light-chain Amyloidosis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            July 22, 2021

                            Lead Product(s) : Birtamimab

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Amryt Pharma

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Amryt Pharma

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)

                            Details : Lomitapide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Homozygous Familial Hypercholesterolemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 23, 2020

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Prothena

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Prothena

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NEOD001

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloi...

                            Details : NEOD001 is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Immunoglobulin Light-chain Amyloidosis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            December 09, 2014

                            Lead Product(s) : NEOD001

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth